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Reduced sensitivity of human immunodeficiency virus type 1 (HIV-1) to protease inhibitors is associated with multiple
amino acid substitutions in the virus-encoded protease. The combination of changes that contribute to drug resistance is
dependent in part upon the amino acid residues comprising protease alleles prior to drug therapy. We analyzed within
peripheral blood mononuclear cells from HIV-1-infected mothers and their children viral gag/pol regions, which included
p7, transframe p6/p6*, and protease coding sequences, as well as six protease cleavage sites. Sixty protease alleles from
12 individuals differed by at least 3 to as many as 10 amino acids from proteases encoded by molecular clones of HIV-1,
indicating that there is no prototype or consensus wild-type HIV-1 protease sequence. Protease variants with a proline at
position 63, a substitution associated with resistance to protease inhibitors, appeared in the absence of antiprotease therapy
in 7 patients and were transmitted by 2 mothers to their infants. Gag p7 and p6 regions were significantly more variable
than protease. The p6/p6* region contained length variants and amino acid repeats in both reading frames. Five protease
cleavage sites (B, D*, D, E, and F) contained highly conserved amino acid sequences in individuals infected by epidemiologi-
cally distinct viruses. In contrast, C cleavage sites, localized between Gag p2 and Gag p7, displayed considerable amino
acid variability, were unique among groups of infected individuals, and appeared to be related to particular protease alleles.
Genetic variability in vivo in protease, in cleavage sites, and in proteins upstream of protease provides the potential to
modulate enzyme activity and susceptibility to protease inhibitors. q 1996 Academic Press, Inc.
INTRODUCTION acid substitutions in Gag and Pol that may develop in
response to immune pressures is constrained by func-
Genetic variability in human immunodeficiency virus
tional selection for production of mature, infectious, repli-
type 1 (HIV-1) can influence infectivity and pathogenesis
cation-competent virions.
of the virus, as well as provide a mechanism for virus
Treatment of HIV-1-infected individuals with antiret-
escape from immune surveillance and antiviral drugs
roviral drugs introduces another selective pressure that
(Coffin, 1995). Highly variable env domains evolve contin-
contributes to emergence of viruses with reduced sensi-
uously within infected individuals in response to selec- tivity to inhibitors. The first series of antiviral drugs was
tive pressures exerted by host immunity and tropism for targeted at reverse transcriptase and resulted in muta-
different cell types. The gag and pol regions of the HIV-1 tions in the enzyme that could confer cross-resistance
genome encode virion structural proteins and enzymatic to related classes of antiviral compounds (Mellors et al.,
activities essential at multiple steps in the virus life cycle 1994). A second target for antiviral drugs is HIV-1 prote-
(Kaplan et al., 1993; Kohl et al., 1988; Nagy et al., 1994). ase, which is absolutely required for virion maturation
Gag and Pol proteins contain immunological epitopes and infectivity (Graves, 1991; Debouck, 1992; Swanstrom,
and provide targets for both cellular and humoral immune 1994). HIV-1 protease contains 99 amino acids and func-
responses in HIV-1-infected individuals (Janvier et al., tions as a homodimeric enzyme to cleave the polyprotein
1991; Kinney et al., 1991). However, the extent of amino precursors Pr55gag, which includes virion structural pro-
teins, and Pr160gag-pol, which includes both structural pro-
teins and the viral enzymes protease, reverse tran-1 Current address: Department of Surgery, Yale University College
of Medicine, New Haven, CT. scriptase/ribonuclease H, and integrase (Katz and
2 Current address: Gene Genie, Inc., Providence, RI. Skalka, 1994). Pr160gag-pol fusion polyprotein is translated3 To whom correspondence and reprint requests should be ad-
with a low frequency as a result of a ribosomal frameshift.dressed at Box 100275, University of Florida College of Medicine,
Distinct amino acid changes in protease occur in re-Gainesville, FL 32610-0275. Fax: (352) 392-0481; E-mail: goodenow.
pathology@mail.health.ufl.edu. sponse to inhibitors in vivo and in vitro (El-Farresh et al.,
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well defined, although there is evidence that the C site
may be the first target (Tritch et al., 1991). Variability
within cleavage recognition sites would affect rates of
cleavage and impact protease activity.
Regions upstream of protease can influence protease
autoprocessing and contribute to budding of virions from
the cell surface (Gottlinger et al., 1991; Partin et al., 1991;
Pettit et al., 1994; Zybarth and Carter, 1995). For example,
the transframe region, designated p6*, is located down-
stream of the ribosomal frameshift and is translated in
the same reading frame as protease in the Pr160gag-pol
polyprotein (Fig. 1). p6* may be involved in protease acti-
vation because deletion of the domain increases auto-
processing of Gag–protease precursors in vitro (Partin
et al., 1991). Genetic variability in p6*, if it occurs, would
present an additional factor in modulating protease activ-
ity and production of infectious virions.
The focus of our studies was to discover the extent of
FIG. 1. Region of HIV-1 gag/pol amplified from patients. The region genetic variability in HIV-1 protease in a cohort of in-
extended from p24 through RT and included six protease cleavage fected individuals prior to administration of protease in-
sites. Sites B and C flank p2 between p24 and p7, sites D* and D flank hibitors. We were particularly interested in the spectrum
p1 between p7 and p6, and sites E and F flank protease. The ribosomal
of protease alleles in vivo in uncultured viruses relativeframeshift occurs just before the D and D* sites, which results in a
to proteases from molecular clones of HIV-1, which werechange in reading frame that produces p6* and the pol-encoded en-
zymes. Forward primer 1 in combination with reverse primer 2 or 3 generally derived from cultured viruses and are used for
was used for amplification. Primers 4 and 5 were used to amplify evaluation of protease inhibitors prior to clinical trials. A
protease for use as a probe. Primers 4, 6, and 7 were used for sequenc- second goal was to assess genetic variation in regions
ing. Precise sequence and location of primers are included under Mate-
upstream of protease and in target cleavage sites be-rials and Methods.
cause of their potential to modulate protease activity. We
analyzed HIV-1 gag/pol regions from a cross-section of
four mothers, who were infected by heterosexual trans-1994; Fontenot et al., 1992; Ho et al., 1994; Kaplan et al.,
1994; Markowitz et al., 1995; Mellors et al., 1994; Myers mission, and eight children infected by maternal trans-
mission or blood transfusion. Our results revealed combi-et al., 1994; Otto et al., 1993; Partaledis et al., 1995; Patick
et al., 1995; Wei et al., 1995; Winslow et al., 1995). A nations of amino acids in protease that were fixed among
viruses with epidemiological linkages. Regions in gag p7number of amino acid substitutions impart increased re-
sistance and cross-resistance of protease to multiple and p6/p6* were more variable than protease. Protease
cleavage site C between p2 and p7 was unusual amonginhibitors (Condra et al., 1995; Gulnik et al., 1995). The
spectrum of amino acid substitutions that can contribute the cleavage sites because the amino acid composition
appeared to be related to particular proteases. Our re-to reduced drug sensitivity of protease are complicated
and have only begun to be identified (Baldwin et al., 1995; sults indicate that genetic variability in vivo in protease,
in cleavage sites, and in proteins upstream of proteaseCollins et al., 1995; Moody et al., 1995). One factor that
appears to determine substitutions is the amino acid provides the potential to modulate protease activity and
susceptibility to inhibitors.sequence of a particular protease allele prior to drug
exposure (Lin et al., 1995).
The HIV-1 Gag/Pol polyprotein presursors contain at MATERIALS AND METHODS
least eight protease cleavage sites, which are not homo-
Patients and samples
geneous but fall into one of three categories. Class I
sites, with an aromatic amino acid and proline flanking Peripheral blood samples were collected from HIV-1-
infected mothers and children after obtaining informedthe scissile peptide bond, are found at either end of
protease itself (sites E and F) and between p17 and p24 consent under protocols approved by the Institutional
Review Board of the University of Florida College of Medi-in Gag (site A) (Fig. 1). Class II cleavage sites contain a
hydrophobic amino acid and either glutamine or gluta- cine. Four families of mothers and children infected by
maternal transmission were studied (Table 1). In Familiesmate, which characterize cleavage sites B, C, D*, and D
in Gag (Fig.1). A third class of sites, which lack any se- C and E, each mother (designated MC or ME) had one
infected child, C1 or E1, respectively. Family D includedquence features in common with the Class I or Class
II sites, appears in reverse transcriptase. The order of a mother, MD, and two infected children, D1 (the first
child) and D2 (the second child). Family B includedprotease processing at the various cleavage sites is not
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TABLE 1 HIVLAI) (Myers et al., 1994) and reverse primer 5* TCC-
TACATACAAATCATC 3* (nucleotides 2710–2684) (Fig. 1,Summary of Patients and Samples
primers 1 and 2, respectively). The forward primer in
combination with a second reverse primer 5* TTGGAA-Sample CDC
Individual date Age stagea ZDV TATTGCTGGTGAT 3* (nucleotides 2614 to 2596) was
used for the second round of amplification (Fig. 1, primer
Family B 3). Amplification reactions were carried out in a Perkin–
MB 10/91 B3 0
Elmer 4800 Tempcycler and included an initial denatur-B3 10/91 1 month A1 0
ation at 957 for 10 min, followed by 35 cycles each con-B2 10/91 1.6 years C3 0
B2.2 11/91 1.7 years C3 / sisting of denaturation at 957 for 1 min, primer annealing
B1 8/91 4.5 years C3 / at 557 for 30 sec, and extension at 727 for 3 min, and a
Family C final elongation at 727 for 10 min. Sensitivity and specific-
MC 6/90 A1 /
ity of the primers, as well as the accuracy of Taq polymer-C1 7/90 2 months A3 /
ase, were assayed using DNA from 8E5 cells, obtainedFamily D
MD 11/90 C3 / from the AIDS Research and Reference Reagent Pro-
D1 11/90 2.5 years A1 / gram, Division of AIDS, NIAID, NIH (Folks et al., 1986).
D1.2 6/91 3.1 years A2 / Amplified products were analyzed by gel electrophoresis
D2 6/91 2.2 years A1 /
and hybridization with a 300-bp DNA probe derived by am-D2.2 9/93 3.5 years A2 /
plification of protease from a molecular clone of HIVLAIFamily E
ME 11/88 B2 / (Peden et al., 1991) with forward 5* CCCTCAGATCACTCT-
E1 11/88 1.9 years C2 0 TTGGCAACGAC 3* and reverse 5* AAAATTTAAAGTGCA-
E1.2 09/89 2.8 years C3 0 ACCAATCTG 3* primers (Fig. 1, primers 4 and 5). The frag-
Family Fb
ment was purified by isolation on DEAE membrane, elutionMLS1 6/91 7.7 years A1 /
in high-salt NET (1 M NaCl, 0.1 mM EDTA, and 20 mMMLS2 8/92 8.9 years A1 /
Tris, pH 8) buffer, and ethanol precipitation. The probe was
a CDC classification for infection in children (CDC, 1994). labeled by the random primer method with [32P]dATP to a
b Child was infected by neonatal transfusion and is now 12 years of specific activity of 1 to 3 1 109 cpm/mg DNA. Blots were
age with normal CD4 T lymphocyte levels. hybridized at 607 for 16 hr with 11 106 cpm of radiolabeled
probe per milliliter of buffer and washed for 1 hr at 607, as
described previously (Aleixo et al., 1995).mother MB and three infected children, B1, B2, and B3
Products amplified from patient DNA were cloned us-(numbered to reflect birth order). Child F (MLS) was in-
ing the pGEM-T vector system (Promega) and competentfected in 1983 by a neonatal blood transfusion and is
DH5a strain of Escherichia coli. Ampicillin-resistant colo-a long-term survivor with normal CD4 levels (Table 1).
nies were screened by hybridization with the proteaseAlthough some of the individuals received zidovudine
probe. Inserts in recombinant plasmid DNA were ana-(ZDV), none of the mothers was enrolled in the ACTG 076
lyzed by digestion with ApaI or PstI restriction enzymesprotocol. Neither mothers nor children received antiviral
before purification by column chromatography (Qiagen).therapy involving protease inhibitors.
Sequencing an 800-bp region of the amplified, cloned
fragment was performed using forward primer 5* CAGGGA-
Amplification, cloning, and sequencing GTGGGAGGA 3* (nucleotides 1386 to 1400) and reverse
primer 5* ACTTTTGGGCCATCCATTCCTGGC 3* (nucleo-Peripheral blood mononuclear cells (PBMC) were frac-
tides 2193–2170) (Fig. 1, primers 6 and 7). Sequences weretionated by Ficoll Hypaque centrifugation, counted, and
generated using Sequenase Version 2.0 (U.S. Biochemi-lysed for DNA extraction. DNA was purified using the
cals) or cycle sequencing and an automated ABI 373Asalt extraction method (Gnome DNA Isolation kit; Bio101,
sequenator. The error frequency of Taq polymerase wasInc., La Jolla, CA) and quantified by spectrophotometer.
determined by amplification, cloning, and sequencing theA 1.7-kb region, which extended from the 5* end of gag
target region from 8E5 DNA (Saiki et al., 1988; Goodenowp24 into reverse transcriptase in pol, was amplified using
et al., 1989). The calculated error frequency in our proce-nested primers and two rounds of amplification (Fig. 1).
dure was 0.2% and the misincorporation rate was 1.1 1Each reaction was carried out in 50 ml containing 0.5 to
1004 per nucleotide per cycle. None of the nucleotide sub-1 mg genomic DNA, 2.25 mM MgCl2 , 50 mM KCl, 20 mM stitutions in our control experiments produced a change inTris (pH 8.2), 100 mg bovine serum albumin per milliliter,
the deduced amino acid sequence.200 mM each deoxynucleotide triphosphate, 1.25 U Taq
Sequence analysis, gag/pol database, and GenBankpolymerase, and 100 or 500 nM each primer in first or
Accession Nos.second round, respectively. First-round amplification was
performed with forward primer 5* GTTAAAAGAGACCAT- Nucleic acid sequences were aligned (COMPARE in
the DNA Sequence Alignment Editor 2.4, Dr. Alan Goldin,CAAT 3* (corresponding to nucleotides 935 to 953 in
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Department of Biology, Cal Tech, 1994) and translated
(Gene Runner 3.0 for Windows, Hastings Software, Inc.,
1994). Distances within and between populations, includ-
ing analysis of nonsynonymous and synonymous dis-
tances, were calculated using SYNO and SEND (Nei and
Jin, 1989). Phylogenetic analysis was performed using
neighbor-joining with the Kimura two-parameter distance
matrix and parsimony (PHYLIP) (Felsenstein, 1993). Boot-
strap analysis based on 100 bootstrap trees was used
to determine confidence levels for branches in both types
of trees.
To analyze the sequence results from our cohort of
patients in relation to other results, we compiled in DOS
a database comprising more than 250 protease and gag
p7/p6 sequences that were determined for molecular
clones of HIV-1 or amplified from patient PBMC or from
primary isolates in culture (Condra et al., 1995; El-Farresh
et al., 1994; Fontenot et al., 1992; Gulnik et al., 1995; Ho
FIG. 2. Phylogenetic tree of pol. Sequences are designated according
et al., 1994; Kaplan et al., 1994; Markowitz et al., 1995; to Table 1, with different families indicated by letters (B, C, D, and E),
Mellors et al., 1994; Myers et al., 1994; Otto et al., 1993; mothers by letter (M), and children by a number that represents birth
order (if more than one infected sibling is included). Numbers after thePartaledis et al., 1995; Patick et al., 1995; Wei et al., 1995;
decimal point indicate sequences determined from individual clones.Winslow et al., 1995). Nucleotide sequences that we as-
Amino acid sequences are included in Fig. 3. Numbers on treesembled were edited, formatted for analysis, and trans-
branches are bootstrap values from 100 replicate analysis.
lated into amino acid sequences. Translations included
both reading frames downstream of the ribosomal
frameshift. rived from 10 molecular clones of HIV-1: LAI, SF2, RF,
Sequences from our patients have been submitted to NL4-3, MN, JRCSF, JRFL, HAN, CAMI, and YU2 (Myers et
the Los Alamos Database and to Genbank with Acces- al., 1994). Intrapopulation genetic distances in protease
sion Nos. U53606–U53666. among the infected individuals was 4.3% ({0.6%), which
was similar to the intrasequence variability of 3.2%
({0.5%) among proteases from molecular clones (TableRESULTS
2). Intragroup values within infected individuals ranged
The gag/pol sequences within infected individuals from 8 to 10.6% for gag p7 and 6.9 to 8.7% for gag p6.
Divergence among in vivo sequences was higher thanGenetic distances in both gag and pol from two popu-
the intragroup divergence among molecular clones oflations of sequences were evaluated. One population of
HIV-1, where p7 ranged from 4.5 to 6.1% and p6 se-sequences was derived from PBMC obtained from four
quences ranged from 3.8 to 5.4%. Differences betweeninfected mothers and eight children in our cohort. The
the two populations in gag p7 or p6 were statisticallysecond population included sequences that were de-
significant (P  0.005 for p7 and P  0.01 for p6). When
p6* sequences among molecular clones were analyzed,
genetic distances in the open reading frame of p6* (3.8TABLE 2
to 5.6%) were similar to p6 and protease values (Table
Intragroup Genetic Distance in HIV-1 gag (p7 and p6)
2). In contrast, intragroup genetic distance for p6* amongand pol (p6* and Protease)
sequences from mothers and children ranged from 8.7
to 11.5% (10.1 { 1.4%), which was more similar to p6% variability (//0 SD)a
than to protease, even though protease is in the same
gag pol reading frame as p6*.
Source of HIV-1 p7 p6 p6* protease
Phylogenetic analysis
Infected individuals 9.3 (1.3) 7.8 (0.9) 10.1 (1.4) 4.3 (0.6)
Molecular clonesb 5.3 (0.8) 4.6 (0.8) 4.7 (0.9) 3.2 (0.5) Two methods were used to construct phylogenetic
trees based on protease sequences to assess the rela-
a Intergroup distances between infected individuals and molecular tionships among viruses. Viruses from a mother and her
clones were gag p7, 7.1% ({0.1%); gag p6, 7.6% ({0.2%); and protease,
children clustered together in a neighbor-joining tree and4.0% ({0.2%).
were distinct from viruses infecting other mothers andb Molecular clones included LAI, SF2, RF, NL4-3, MN, JRCSF, JRFL,
HAN, CAM1, and YU2. children (Fig. 2). Similar relationships among protease
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sequences were identified by parsimony analysis (data a single nucleotide change within a codon. Amino acid
changes at positions 35, 37, or 39 were usually associ-not shown). HIVLAI is the only outlying sequence shown in
the tree (Fig. 2). We included in the phylogenetic analysis ated with amino acid substitutions at positions 62, 63, or
64. For example, aspartic acid at residue 35 (D35) wasprotease sequences from a number of molecular clones
of HIV-1, which were derived from passage in culture found in conjunction with proline at residue 63, whereas
asparagine at residue 37 (N37) was associated with 62(Myers et al., 1994). Protease sequences from molecular
clones did not represent a subpopulation of protease, valine (V62), 63 proline (P63), or 64 valine (V64). Threo-
nine at both positions 37 and 39 (T37 and T38) wasbut mapped to branches that were separate from one
another and from sequences found within infected indi- usually associated with V62 and P63. To rule out the
possiblity that the combinations of amino acids in theseviduals (data not shown).
Close epidemiological linkages were found between positions reflected epidemiological linkages among our
sequences, we analyzed protease sequences in the da-protease genes from a mother and her children near to
the time of delivery; for example, MB and B3 at 1 month or tabase that we compiled from a variety of unrelated vi-
ruses. Sixty-nine percent of protease alleles that con-MC and C1 at 2 months. Clear epidemiological linkages
between mother/child viruses persisted for as long as tained D35 also had P63, while 81% of proteases with
N37 contained V62, P63, or V64.3.5 years, in the case of MD and her child D2, or 4.5
years in MB and B1 (Fig. 2). We analyzed the amino acid substitutions in protease
that we found in the absence of protease inhibitorsPhylogenetic analysis of p7, p6, or the entire amplified
region of gag/pol resulted in relationships that were es- among our cohort in relation to our database of protease
sequences. Among more than 250 natural protease al-sentially the same as the tree based on protease se-
quences (data not shown). In addition, the linkages that leles, amino acid substitutions occurred in 45 of 99 posi-
tions (Fig. 4). Several positions in the amino half of theappeared from analysis of gag or pol sequences from
mother and children in Family B were similar to phyloge- enzyme, for example, positions 10, 12, 19, and 37, could
contain any one of 6 to 7 different amino acids. In con-netic clustering of sequences from Family B when env
V1 and V2 (Lamers et al., 1994) or nef/LTR regions trast, substitutions in the flap region occurred infre-
quently and with limited variety. Amino acid substitutions(M. M. Goodenow et al., in preparation) were analyzed.
between positions 78 and 91 were found only in rare
natural alleles.Deduced amino acid sequences of protease alleles
When the database of sequences from proteases
which were drug resistant was analyzed, we found thatThe majority of nucleotide changes in the gag/pol re-
gion involved silent substitutions, resulting in a ratio of resistance to protease inhibitors involved changes in 20
of 99 amino acids, of which about half appeared within1.0 for nonsynonymous to synonymous substitutions
(data not shown). However, a portion of nucleotide the catalytic domain, the flap region, or the c loop (Fig.
4). Substitutions between amino acids 81 and 90 werechanges would result in amino acid differences in prote-
ase (Fig. 3). None of the proteases detected in uncultured prevalent in protease alleles with reduced sensitivity to
various inhibitors. Amino acid changes at four positionsPBMC in vivo from infected mothers or children in our
cohort was identical in amino acid composition to prote- (L10F or R, L63P, A71V, and V75I), which appear in re-
sponse to some protease inhibitors, can be found amongases found in molecular clones of HIV-1, many of which
were derived from cultured HIV-1 (Myers et al., 1994). protease alleles in patients without selection by protease
inhibitors. A proline at position 63 appeared within theIndividual alleles from patients differed from alleles in
molecular clones by at least 3 to as many as 10 amino protease sequences from seven individuals in our cohort,
including mothers MB and MD and their children B3 andacids. Substitutions appeared in 29 of 99 (30%) amino
acid positions in protease, but were generally localized B2 or D1 and D2, respectively; rapid progressors, for
example infant B3 who died at about 1 year of age; andto regions other than the catalytic site, the flap region,
or the c loop. For example, with a single exception in long-term survivors, for example patient MLS in Family
F (Fig. 3).D1, no substitutions occurred between amino acids 21
and 33, which surrounded the catalytic aspartate at posi-
tion 25 (Fig. 3). A minority of five protease alleles from Protease target sites in Gag/Pol precursor
four different individuals (B3, D1, E1, and MLS) had sub- polyprotein
stitutions in the flap region. Two alleles contained glu-
tamic acid in place of glycine at position 48 and three Target sequences at cleavage sites B, D*/D, E, and F
displayed restricted amino acid variation relative to thehad lysine or arginine in place of glycine at position 51.
Only two sequences (one from B2 and one from MLS) array of protease sequences. The predominant residues
among viruses in vivo from our cohort were identical todisplayed arginine substitutions for glycine at position
86 in the c loop (Fig. 3). the sequence found in HIVLAI or other molecular clones
of HIV-1 (Fig. 5). For example, among all patients weThe majority of amino acid substitutions resulted from
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FIG. 3. Natural protease alleles from mothers and children. Single-letter amino acid code is used. Dashes indicate identity with the reference
sequence, HIVLAI ; differences are designated by a letter. Protease sequences from six molecular clones of HIV-1 are included directly under HIVLAI .
Numbers of identical amino acid sequences are indicated in parentheses. None of the clones had identical nucleotide sequences.
FIG. 4. Summary of amino acid substitutions in protease in the absence and presence of protease inhibitors. Sources of sequences are referenced
under Material and Methods. Between the reference sequence, which is HIVLAI , and the horizontal line, amino acid substitutions from our studies
are summarized in bold uppercase letters and from other studies in lowercase letters. All amino acids above the horizontal line are from proteases
in the absence of protease inhibitors. Below the horizontal line are amino acids associated with reduced sensitivity or resistance to protease
inhibitors. Shaded sequences indicate amino acid residues associated with resistance that are found in proteases from patients in the absence of
inhibitors.
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FIG. 5. Summary of cleavage site sequences in Gag and Pol among patients in vivo. The asterisk indicates the cleavage site. Ten amino acids
(designated P5, P4, P3, P2, P1 * P1*, P2*, P3*, P4*, P5*) define the substrate peptide that binds in the active site of protease. Numbers in parentheses
designate the families in which particular C site peptides were identified: 1, Families B and C; 2, Family B; 3, Family C; 4, Family D; 5, Family E.
studied, 73% of the B cleavage site sequences, 88% of HIVLAI contains the duplication, which also appeared
prominantly in Family D and in several clones from thethe D* sequences, and 82% of the F site sequences were
identical to the B, D*, or F cleavage sites in HIVLAI . At child in Family E. Gag p6 in HIVLAI contains 12 proline
residues, most of which are preserved in p6 withinthe D site, 41% of the patient sequences were identical
to HIVLAI and 40% had asparagine and threonine substitu- HIV-1-infected individuals. Length variation was re-
flected as well in p6*, the transframe peptide that over-tions at positions P3* and P5* or lysine at P3*. A substitu-
tion of serine for asparagine in the P2 position of the E laps p6 and is translated when the ribosomal
frameshift occurs. Even though nucleic acid variationcleavage site of most in vivo sequences differed from
HIVLAI , but was similar to the E site in other molecular ranged from about 8 to 10% in the region of p6 and
clones including NL4-3, RF, or YU2. One consequence
of the limited repertoire of cleavage amino acids was
that the same cleavage sequences appeared in individu-
als from different families independent of the epidemiol-
ogy of the viruses.
In contrast to the majority of cleavage sites, the C
cleavage site was unique from several perspectives. The
C cleavage site displayed the most variability with as
many as 16 different target sequences. No dominant se-
quence defined the C cleavage site. Only 19% of C site
sequences from patients were identical to HIVLAI . In most
cases, C site sequences were specific for individuals
infected by epidemiologically related viruses (Fig. 5).
Amino acid sequences of p7, p6, and p6*
Regions upstream of protease in the Gag/Pol polypro-
tein had amino acid sequences that were characteristic
for each family of mothers and children (Fig. 6). The domi-
nant p7 proteins in each family differed from p7 in HIVLAI
at one to three amino acids. Single amino acid substitu-
tions, many involving changes between basic residues
arginine and lysine, were found in different variants
within members of each family. Multiple cysteine and
histidine residues constituting two zinc binding motifs
FIG. 6. Summary of amino acid substitutions in Gag p7 and p6 andinvolved in interactions between p7 and virion RNA (Gor-
Pol p6* in HIV-1 in patients. HIVLAI is used as the reference sequence.elick et al., 1993) were essentially invariant in all se-
Gaps indicated by dashes are introduced to maximize alignments. As-
quences in our patients (Fig. 6). terisks in p7 designate the cysteine and histidine residues that consti-
Variation in p6 was characterized by length variation tute the two zinc binding motifs. ˆ in p6 marks the proline residues.
Horizontal lines designate repeat sequences in p6 and p6*.resulting from duplications of 6 to 10 amino acids.
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p6*, the reading frames remained intact in the infected
mothers and children.
DISCUSSION
The spectrum of HIV-1 protease alleles in vivo in the
absence of drug selection continues to expand as more
infected individuals are examined. The picture which
emerges is one of an enzyme with more plasticity than
would be predicted by its size, just 99 amino acids, and
by the specificities of the interactions between the homo-
dimeric enzyme and the peptide substrates that are re-
quired for catalysis. Analysis of protease sequences from
our cohort of infected mothers and children, in conjunc-
tion with protease alleles compiled in our database, re-
FIG. 7. Monomeric form of HIV-1 protease. Amino acid residues 35vealed that natural amino acid substitutions are localized
to 39 and 62 to 64 are indicated by numbers and black regions. Flap
to domains which are not involved directly in enzyme is folded over the substrate cleft and active site. D25 indicates the
function. By and large, the polymorphic regions in natural catalytic aspartic acid.
variants of protease mirrored domains identified by ex-
tensive mutagenesis of the molecule (Loeb et al., 1989).
However, one striking aspect of natural protease alleles Although the impact of these amino acids on efficacy of
protease inhibitors in patients has not been examined inis the spectrum of amino acids that can appear in certain
positions, such as amino acid residues 10, 11, 19, and most cases, the possibility exists that natural protease
variants will exhibit different sensitivities to drugs, which37, most of which have not been analyzed by in vitro
mutagenesis. The number of amino acid differences could impact efficacy.
Alternatively, polymorphisms in protease alleles couldamong more than 250 protease alleles means that there
is no dominant, wild-type protease sequence. Neither include compensatory amino acid substitutions that ef-
fectively neutralize the impact of any single amino aciddoes a consensus protease sequence emerge from an
analysis of our database of natural alleles, indicating that change. Combinations of amino acids in positions 35,
37, or 39 and 62, 63, or 64 in proteases appeared inno individual protease is necessarily representative of
the array of HIV-1 proteases in vivo. If amino acid differ- epidemiologically related viruses in mothers and chil-
dren. Preservation of the amino acids over time withinences result in functional variation, then evaluation of
efficacy of protease inhibitors will require expanding the multiple individuals and after transmission from one per-
son to another suggests that there could be functionalpanel of protease alleles included in drug screens. We
have evidence from kinetic assays that all natural prote- advantages for specific combinations of amino acids.
Based on the crystal structure of protease (reviewed byase alleles are not functionally equivalent (W. Leelamanit,
M. M. Goodenow, and B. M. Dunn, in preparation). Wlodawer and Erickson, 1993), positions 35, 37, 39, and
62 to 64 are localized to regions of the enzyme at theHigh-level resistance to protease inhibitors involves a
progression of amino acid substitutions, many of which beginning of the flap region (Fig. 7). Combinations of
amino acids in these positions could exert subtle influ-occur in regions of the enzyme that are relatively invariant
in the absence of antiprotease drug therapy. The number ences on the substrate cleft and active site of the en-
zyme.and location of amino acids conferring reduced sensitiv-
ity to drug predicts that preexisting, high-level drug-resis- The catalytic activity of protease is complicated by
factors other than amino acid sequence of the enzymetant variants of protease would not be commonly found
in the untreated individual. This generally appears to be itself. For example, protease is initially synthesized as
part of a large polyprotein precursor, which means thatthe situation, with two important reservations. First, the
number of infected individuals and HIV-1 protease se- the primary structure of surrounding proteins could com-
pensate for amino acid substitutions in the enzyme. Ourquences that have been examined is still limited relative
to the extent of HIV-1 in the population. Second, a single studies included an appraisal of proteins preceding the
amino terminus of protease in the Gag/Pol polyprotein.amino acid substitution in protease (proline at residue
63), which is associated with progression to high-level Variability in p7, p6, and p6* in vivo involved amino acid
substitutions and, in some patients, length variation asdrug resistance, was detected in untreated individuals
in our studies. A proline residue at position 63 occurs in long as five to eight amino acids, which could be signifi-
cant for protease function (Zybarth and Carter, 1995).vivo in about 50% of the patients infected by subtype B
viruses, while amino acid changes at residues 10, 12, The precise and intimate association between target
cleavage sites and the substrate cleft in protease neces-71, or 73 were less frequent in the untreated population.
AID VY 7906 / 6a16$$$121 04-22-96 17:47:49 vira AP: Virology
415NATURAL GENETIC VARIABILITY IN HIV-1 GAG/POL
Collins, J. R., Burt, S. K., and Erickson, J. W. (1995). Flap opening insitates evaluation of natural cleavage sites, which was
HIV-1 protease simulated by ‘activated’ dynamics. Nat. Struct. Biol.a unique aspect of our analysis. Even though protease
2, 334–338.
alleles were patient specific, most target cleavage sites Condra, J., Schleif, W., Blahy, O., Gabryelski, L., Graham, D., Quintero,
were universal and appeared in essentially identical form J., Rhodes, A., Robbins, H., Roth, E., Shivaprakash, M., Titus, D., Yang,
T., Teppler, H., Squires, K., Duetsch, P., and Emini, E. (1995). In vivoin different individuals. Therefore, the same or closely
emergency of HIV-1 variants resistant to multiple protease inhibitors.related peptides that characterize each cleavage site
Nature 374, 569–571.serve as substrates for a spectrum of proteases. In gen-
Debouck, C. (1992). HIV-1 protease as a therapeutic target for AIDS.
eral, compensatory changes in cleavage sites are appar- AIDS Res. Hum. Retroviruses 8, 153–164.
ently not required to maintain interactions with the multi- Dorfman, T., Luban, J., Goff, S. P., Haseltine, W. A., and Gottlinger,
H. G. (1993). Mapping of functionally important residues of a cys-ple variants of the enzyme. An exception is the C cleav-
teine–histidine box in the human immunodeficiency virus type 1age site located between p2 and p7 in the Gag
nucleocapsid protein. J. Virol. 67, 6159–6169.polyprotein. In contrast to the other cleavage sites, amino
El-Farrash, M. A., Kuroda, M. J., Kitazaki, T., Masuda, T., Kato, K., Ha-
acids comprising the C site segregated by epidemiology, tanka, M., and Harada, S. (1994). Generation and characterization of
implying that a critical association may exist between a a human immunodeficiency virus type 1 (HIV-1) mutant resistant to
an HIV-1 protease inhibitor. J. Virol. 68, 233–239.particular protease allele and its cognate C target pep-
Felsenstein, J. (1993). PHYLIP (phylogeny interference package), Ver-tide. There is evidence that the C site is the first site
sion 3.5c. Department of Genetics, University of Washington, Seattle.cleaved in Gag/Pol processing, suggesting some affinity
Folks, T. M., Powell, D., Lightfoote, M., Koenig, S., Fauci, A. S., Benn,
between the C site and the conformation of protease in S., Rabson, A., Daugherty, D., Gendelman, H. E., Venkatesan, S., and
the polyprotein precursor (Tritch et al., 1991). We are Martin, M. A. (1986). Biological and biochemical characterization of
a cloned Leu-3-cell surviving infection with the acquired immuneinvestigating how protease function can be modulated
deficiency syndrome retrovirus. J. Exp. Med. 164, 280–290.by different Gag and cleavage site combinations.
Fontenot, G., Johnston, K., Cohen, J. C., Gallaher, W. R., Robinson, J., andAntiviral drugs provide a prospect for controlling HIV-
Luftig, R. B. (1992). PCR amplification of HIV-1 proteinase sequences
1 infection. For example, the exciting results from ACTG directly from lab isolates allows determination of five conserved do-
076 demonstrate that maternal transmission of HIV-1 can mains. Virology 190, 1–10.
Goodenow, M. M., Huet, T., Saurin, W., Kowk, S., Sninsky, J., and Wainbe significantly impaired by ZDV, a drug targeting reverse
Hobson, S. (1989) HIV-1 isolates are rapidly evolving quasispecies:transcriptase. We know that HIV-1 will change in re-
Evidence for viral mixtures and preferred nucleotide substitutions. J.sponse to immunological or pharmacological pressures.
Acquired Immune Defic. Syndr. 2, 344–352.
The challenge is to force the virus to change in directions Gorelick, R. J., Chabot, D. J., Rein, A., Henderson, L. E., and Arthur,
that reduce pathogenicity, replicative ability, or escape L. O. (1993). The two zinc fingers in the human immunodeficiency
virus type 1 nucleocapsid protein are not functionally equivalent. J.from immune response. The emerging picture of prote-
Virol. 67, 4027–4036.ase and its targets in infected individuals prior to prote-
Gottlinger, H., Dorfman, T., Sodroski, J., and Haseltine, W. (1991). Effectase inhibitors provides the basis for following emergence
of mutations affecting the p6 gag protein on human immunodefi-
of resistant variants once therapy is initiated. ciency viral particle release. Proc. Natl. Acad. Sci. USA 88, 3195–
3199.
Graves, M. (1991). HIV proteinase: Now, then, what’s next? In ‘‘StructureACKNOWLEDGMENTS
and Function of the Aspartic Proteinases’’ (B. M. Dunn, Ed.). Plenum,
This research was supported by Public Health Service Grant AI28571 New York.
(B.M.D. and M.M.G.), by American Foundation for AIDS Research Gulnik, S. V., Suvorov, L. I., Liu, B., Yu., B., Anderson, B., Mitsuya, H., and
AmFAR (M.M.G.), by Pediatric AIDS Foundation Student Award (K.A.B.), Erickson, J. W. (1995). Kinetic characterization and cross-resistance
and by National Research Service Award GM15899 (E.E.P.). The au- patterns of HIV-1 protease mutants selected under drug pressure.
thors are grateful to Keith Peden for providing the molecular clone of Biochemistry 34, 9282–9287.
HIV-1LAI and to Michael Hamner and Kimberly Evans for assistance Ho, D. D., Toyoshima, T., Mo, H., Kempf, D. J., Norbeck, D., Chen, C.,
with sequencing. This article is dedicated to Dr. Frank Lilly, who died Wideburg, N. E., Burt, S. K., Erickson, J. W., and Singh, M. (1994).
October 14, 1995. Frank was my mentor, colleague, and friend who Characterization of human immunodeficiency virus type 1 variants
influenced my career at every step and whose humor and inspiration with increased resistance to a C2-symmetric protease inhibitor. J.
will be missed (M.M.G.). Virol. 68, 2016–2020.
Janvier, B., Baillous, A., Archinard, P., Mounier, M., Mandrand, B.,
Goudeau, A., and Barin, F. (1991). Immune response to a majorREFERENCES
epitope of p24 during infection with human immunodeficiency virus
type 1 and implications for diagnosis and prognosis. J. Clin. Microbiol.Aleixo, L. F., Goodenow, M. M., and Sleasman, J. W. (1995). Molecular
29, 88–92.analysis of highly enriched populations of T cell depleted monocytes.
Kaplan, A. H., Zack, J. A., Knigge, M., Paul, D. A., Kempf, D. J., Norbeck,Clin. Diagn. Lab. Immunol. 2, 733–739.
D. W., and Swanstrom, R. (1993). Partial inhibition of the humanBaldwin, E. T., Bhat, T. N., Liu, B., Pattabiraman, N., and Erickson, J. W.
immunodeficiency virus type 1 protease results in aberrant virus(1995). Structural basis of drug resistance for the V82A mutant of
assembly and the formation of noninfectious particles. J. Virol. 67,HIV-1 proteinase. Nat. Struct. Biol. 2, 244–249.
4050–4055.Centers for Disease Control and Prevention. (1994). Revised classifica-
Kaplan, A. H., Michael, S. F., Wehbie, R. S., Knigge, M. F., Paul, D. A.,tion system for human immunodeficiency virus infection in children
Everitt, L., Kempf, D. J., Norbeck, D. W., Erickson, J. W., and Swan-less than 13 years of age. MMWR 43, 1–10.
strom, R. (1994). Selection of multiple human immunodeficiency virusCoffin, J. M. (1995). HIV population dynamics in vivo: Implications for
genetic variation, pathogenesis, and therapy. Science 267, 483–489. type 1 variants that encode viral proteases with decreased sensitivity
AID VY 7906 / 6a16$$$121 04-22-96 17:47:49 vira AP: Virology
416 BARRIE ET AL.
to an inhibitor of viral protease. Proc. Natl. Acad. Sci. USA 91, 5597– Nei, M., and Jin, L. (1989). Variances of the average numbers of nucleo-
tide substitutions within and between populations. Mol. Biol. Evol. 6,5601.
Katz, R. A., and Skalka, A. M. (1994). The retroviral enzymes. Annu. Rev. 290–300.
Otto, M. J., Garber, S., Winslow, D. L., Reid, C. D., Aldrich, P., Jadhav,Biochem. 63, 133–173.
P. K., Patterson, C. E., Hodge, C. N., and Cheng, Y. S. (1993). In vitroKinney, J. S., Conway, J. H., Hilgartner M. W., et al. (1991). Humoral
isolation and identification of human immunodeficiency virus (HIV)immune responses to Gag and Env proteins from human immunode-
variants with reduced sensitivity to C-2 symmetrical inhibitors of HIVficiency virus type 1 in hemophiliac patients. Am. J. Hematol. 36, 35–
type-1 protease. Proc. Natl. Acad. Sci. USA 90, 7543–7547.41.
Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C.,Kohl, H., Emini, E., Schleif, W., Davis, L. J., Heimbach, J. C., Dixon,
Maschera, B., Myers, R. E., Pazhanisamy, S., Futer, O., and Cullinan,R. A., Scolnick, E. M., and Sigal, I. S. (1988). Active human immunode-
A. B. (1995). In vitro selection and characterization of human immuno-ficiency virus protease is required for viral infectivity. Proc. Natl.
deficieny virus type 1 (HIV-1) isolates with reduced sensitivity toAcad. Sci. USA 85, 4686–4690.
hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.Lamers, S. L., Sleasman, J. W., She, J. X., Barrie, K. A., Pomeroy, S. M.,
J. Virol. 69, 5228–5235.Barrett, D. J., and Goodenow, M. M. (1994). Persistence of multiple
Partin, K., Zybarth, G., Ehrlich, L., Decrombrugghe, M., Wimmer, E., andmaternal genotypes of HIV-1 in infants infected by vertical transmis-
Carter, C. (1991). Deletion of sequences upstream of the proteinasesion. J. Clin. Invest. 93, 380– 390.
improves the proteolytic processing of human immunodeficiency vi-Lin, Y., Lin, X., Long, L., Foundling, S., Heinrikson, R. L., Thaisrivongs,
rus type 1. Proc. Natl. Acad. Sci. USA 88, 4776–4780.S., Leelamanit, W., Raterman, D., Shah, M., and Dunn, B. M. (1995).
Patick, A. F., Rose, R., Greytok, J., Bechtold, C. M., Hermsmeier, M. A.,Effect of point mutations on the kinetics and the inhibition of human
Chen, P. T., Barish, J. C., Zahler, R., Colonno, R. J., and Lin, P. F.immunodeficiency virus type 1 protease: Relationship to drug resis-
(1995). Characterization of a human immunodeficiency virus type 1tance. Biochemistry 34, 1143 –1152.
variant with reduced sensitivity to an aminodiol protease inhibitor. J.Loeb, D., Swanstrom, R., Everitt, L., Manchester, M., Stamper, S., and
Virol. 69, 2148–2152.Hutchinson, C., III. (1989). Complete mutagenesis of the HIV-1 prote-
Peden, K., Emerman, M., and Montagnier, L. (1991). Changes in growthase. Nature 340, 397–400.
properties on passage in tissue culutre of viruses derived from infec-Louwagie, J., McCutchan, F., Peeters, M., Brennan, T., Sanders Buell,
tious molecular clones of HIV-1LAI , HIV-1MAL , and HIV-1ELI . VirologyE., Eddy, G., van der Groen, G., Fransen, K., Gershy-Damet, G. N. M.,
181, 661–672.
Deleys, R., and Burke, D. (1993). Phylogenetic analysis of gag genes
Pettit, S. C., Moody, M. D., Wehbie, R. S., Kaplan, A. H., Nantermet,
from 70 international HIV-1 isolates provides evidence for multiple
P. V., Klein, C. A., and Swanstrom, R. (1994). The p2 domain of human
genotypes. AIDS Res. Hum. Retroviruses 7, 769–780.
immunodeficiency virus type 1 Gag regulates sequential proteolytic
Markowitz, M., Mo, H., Kempf, D. J., Norbeck, D. W., Bhat, T. N., Erickson,
processing and is required to produce fully infectious virions. J. Virol.
J. W., and Ho, D. D. (1995). Selection and analysis of human immuno- 68, 8017–8027.
deficiency virus type 1 variants with increased resistance to ABT- Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn,
538, a novel protease inhibitor. J. Virol. 69, 701–706. G. T., Mullis, K. B., and Erlich, H. A. (1988). Primer-directed enzymatic
Mellors, J., Larder, B., and Schinazi, R. (1994). Mutations in HIV-1 re- amplification of DNA with a thermostable DNA polymerase. Science
verse transcriptase and protease associated with drug resistance. 239, 487–491.
In ‘‘Human Retroviruses and AIDS 1994: A Compilation and Analysis Swanstrom, R. (1994). Characterization of HIV-1 protease mutants: Ran-
of Nucleic Acid and Amino Acid Sequences’’ (G. Myers, S. Korber, dom, directed, selected. Curr. Opin. Biotechnol. 5, 409–413.
S. Wain-Hobson, R. F. Smith, and G. N. Pavlakis, Eds.), pp. III 93– Tritch, R., Cheng, Y., Yin, F., and Erickson-Viitanen, S. (1991). Mutagene-
III 106. Los Alamos National Laboratory, Theoretical Biology and sis of protease cleavage sites in the human immunodeficiency virus
Biophysics, Los Alamos, NM. type 1 gag polyprotein. J. Virol. 65, 922–930.
Moody, M. D., Pettit, S. C., Shao, W., Everitt, L., Loeb, D. D., Hutchison, Wei, X., Ohosh, S., Taylor, M., Johnson, V., Emuni, E., Deutsch, P., Lifson,
C. A., and Swanstrom, R. (1995). A side chain at position 40 of the J., Bonhoeffer, S., Nowak, M., Hahn, B., Saag, M., and Shaw, G. (1995).
human immunodeficiency virus type-1 protease flap provides an ad- Viral dynamics in human immunodeficiency virus type 1 infection.
ditional specificity determinant. Virology 207, 475–485. Nature 373, 117–122.
Myers, G., Korber, S., Wain-Hobson, S., Smith, R. F., and Pavlakis, Winslow, D., Stack, S., King, R., Scarnati, H., Binesik, A., and Otto, M.
G. N. (1994). ‘‘Human Retroviruses and AIDS 1994: A Compilation and (1995). Limited sequence diversity of the HIV-1 protease gene from
Analysis of Nucleic Acid and Amino Acid Sequences.’’ Los Alamos clinical isolates and in vitro susceptibility to HIV protease inhibitors.
National Laboratory, Theoretical Biology and Biophysics, Los AIDS Res. Hum. Retroviruses 11, 107–113.
Alamos, NM. Wlodawer, A., and Erickson, J. W. (1993). Structure-based inhibitors of
Nagy, K., Young, M., Baboonian, C., Merson, J., Whittle, P., and Oroszlan, HIV-1 protease. Annu. Rev. Biochem. 62, 543–585.
S. (1994). Antiviral activity of human immunodeficiency virus type 1 Zybarth, G., and Carter, C. (1995). Domains upstream of the protease
protease inhibitors in a single cycle of infection: Evidence for a role in human immunodeficiency virus type 1 Gag–Pol influence PR auto-
processing. J. Virol. 69, 3878–3884.of protease in the early phase. J. Virol. 68, 757–765.
AID VY 7906 / 6a16$$$121 04-22-96 17:47:49 vira AP: Virology
